The American Association for the Study of Liver Disease (AASLD) recommended surveillance for HCC using ultrasonography with or without alpha-fetoprotein every 6 months in the high-risk individuals: only in cirrhosis and some non-cirrhosis hepatitis B carrier [12]. This evidence concerns the gene AFP and Cirrhosis.